PulseAI, a Belfast, Northern Ireland–based AI-enabled cardiac diagnostics company, has secured Seed funding round.
Investors
The round was led by Innovation Ulster Limited, with participation from The Mortara Group and The Francis Crick Institute.
PulseAI Use of Funds
The company will deploy the capital to scale its AI-based ECG technology, pursue U.S. FDA 510(k) clearance, expand clinical validation efforts, and strengthen enterprise and OEM integrations.
About PulseAI
Founded in 2019 by Dr. Alan Kennedy, PulseAI is a medical technology company specializing in AI-enabled cardiac diagnostics. Its AI-ECG platform is designed to improve the speed, accuracy, and consistency of cardiac diagnosis across both primary and acute care settings. PulseAI’s technology is trained on large-scale ECG datasets and validated in partnership with leading institutions across Europe and the United States. Headquartered in Belfast, Northern Ireland, the company aims to deliver advanced ECG solutions that expedite and improve diagnostic accuracy, reduce clinical variability, and expand access to high-quality cardiac diagnostics across healthcare systems.
Funding Details
Company: PulseAI
Raised: Undisclosed
Round: Seed
Funding Date: January 2026
Lead Investor: Innovation Ulster Limited
Additional Investors: The Mortara Group, The Francis Crick Institute
Company Website: https://www.pulseai.io/
Software Category: AI Healthcare Diagnostics / Medical Imaging & Decision Support
Source: https://www.prnewswire.com/news-releases/pulseai-secures-seed-funding-to-advance-ai-driven-ecg-diagnostics-302658809.html